MyFinsight
Home
Blog
About
logo-vertex-inc-svg copy-svg
VERTEX PHARMACEUTICALS INC MA (VRTX)
logo-vertex-inc-svg copy-svg
VERTEX PHARMACEUTICALS INC MA (VRTX)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$515.6M
Free Cash flow
$3,193.8M
Unit: Million (M) dollars
Positive Cash Flow Breakdown
Sales and maturities of availabl...
Stock-based compensation expense
Interest income
Others
Negative Cash Flow Breakdown
Purchases of available-for-sale ...
Development expenses
Repurchases of common stock
Others
Subscribe for Financial Insights
Page 1
Annual
123
Page 1
Cash Flow
2025-12-31
2024-12-31
2023-12-31
2022-12-31
Product revenues, net
12,001.3
11,020.1
-
-
Cost of sales-Product
601.5
516.3
-
-
Cost of sales-Royalty
1,049.8
1,014.2
-
-
Research expenses
827.9
804.5
-
-
Development expenses
3,081.6
2,825.8
-
-
Acquired in-process research and development expenses
133
4,628.4
-
-
Selling and other commercial expenses
1,102.8
838.5
-
-
General and administrative expenses
650.3
625.8
-
-
Intangible asset impairment charge
379
-
-
-
Interest income
490.9
598.1
-
-
Other segment items
23.1
116.2
-
-
Provision for income taxes
690
784.1
-
-
Income (loss)
3,953.2
-535.6
3,619.6
3,322
Stock-based compensation expense
685.9
698.5
581.2
491.3
Depreciation and amortization expense
209.8
207.2
181.3
148.3
Intangible asset impairment charges
379
-
-
-
Deferred income taxes
-510.8
-348.8
-536.5
-275.9
Losses on equity securities
-
-57.7
-0.6
-149.1
Decrease in fair value of contingent consideration
-
-0.5
-51.6
-57.5
Other non-cash items, net
-113.4
56.3
-8.4
-11.8
Accounts receivable, net
347.3
99.3
84.1
358.6
Inventories
524.2
517.3
322.9
136.4
Prepaid expenses and other assets
396
200.3
545.7
326.4
Accounts payable
36.8
49.5
48.7
120.8
Accrued expenses
-116.9
212.9
429.4
542.5
Other liabilities
148.5
39.7
208.9
498.9
Investment in equity securities and notes receivable
-
-
31
-
Net cash provided by (used in) operating activities
3,631.4
-492.6
3,537.3
4,129.9
Payments related to finite-lived intangible assets
-
-
58
-
Payment to acquire viacyte, inc., net of cash acquired
-
0
0
295.9
Purchases of available-for-sale debt securities
6,396.5
7,438.2
3,786.5
692.7
Sales and maturities of available-for-sale debt securities
5,897.4
4,465.6
839.1
920
Sale of equity securities
-
-
-
0
Purchases of property and equipment
437.6
297.7
200.4
204.7
Proceeds related to equity securities
16
0
95.1
-
Net payments related to finite-lived intangible assets
0
187.7
-
-
Acquisition of available-for-sale debt securities from alpine immune sciences, inc
0
258
-
-
Investment in equity securities and notes receivable
-
-
-
47.8
Other investing activities
24.7
54
-
-
Net cash used in investing activities
-945.4
-3,770
-3,141.7
-321.1
Issuances of common stock under benefit plans
127.7
114.6
134.6
186.3
Repurchases of common stock
2,017.4
1,177.1
427.6
0
Payments in connection with common stock withheld for employee tax obligations
369.9
405
226.1
172
Payments on finance leases
5.4
33.6
44.9
85.5
Proceeds from finance leases
-
-
-
0
Proceeds from finance leases and other financing activities
-
-
1.8
-
Other financing activities
3.7
6.2
-
3.5
Net cash used in financing activities
-2,261.3
-1,494.9
-562.2
-67.7
Effect of changes in exchange rates on cash
90.9
-42.6
26.9
-29.2
Net increase (decrease) in cash, cash equivalents and restricted cash
515.6
-5,800.1
-139.7
3,711.9
Cash and cash equivalents at beginning of period
4,572.2
10,372.3
10,512
6,800.1
Cash and cash equivalents at end of period
5,087.8
4,572.2
10,372.3
10,512
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS).
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Product revenues, net
$12,001.3M
(8.90%↑ Y/Y)
Interest income
$490.9M
(-17.92%↓ Y/Y)
Income (loss)
$3,953.2M
(838.09%↑ Y/Y)
Stock-based compensation
expense
$685.9M
(-1.80%↓ Y/Y)
Intangible asset
impairment charges
$379M
Depreciation and
amortization expense
$209.8M
(1.25%↑ Y/Y)
Other liabilities
$148.5M
(274.06%↑ Y/Y)
Other non-cash items,
net
-$113.4M
(-301.42%↓ Y/Y)
Accounts payable
$36.8M
(-25.66%↓ Y/Y)
Canceled cashflow
$8,539M
Net cash provided by
(used in) operating...
$3,631.4M
(837.19%↑ Y/Y)
Effect of changes in
exchange rates on cash
$90.9M
(313.38%↑ Y/Y)
Canceled cashflow
$1,895.2M
Development expenses
$3,081.6M
(9.05%↑ Y/Y)
Selling and other
commercial expenses
$1,102.8M
(31.52%↑ Y/Y)
Cost of
sales-Royalty
$1,049.8M
(3.51%↑ Y/Y)
Research expenses
$827.9M
(2.91%↑ Y/Y)
Provision for income taxes
$690M
(-12.00%↓ Y/Y)
General and
administrative expenses
$650.3M
(3.91%↑ Y/Y)
Cost of
sales-Product
$601.5M
(16.50%↑ Y/Y)
Intangible asset
impairment charge
$379M
Acquired in-process
research and development...
$133M
(-97.13%↓ Y/Y)
Other segment items
$23.1M
(-80.12%↓ Y/Y)
Net increase
(decrease) in cash, cash...
$515.6M
(108.89%↑ Y/Y)
Canceled cashflow
$3,206.7M
Inventories
$524.2M
(1.33%↑ Y/Y)
Deferred income taxes
-$510.8M
(-46.44%↓ Y/Y)
Prepaid expenses and
other assets
$396M
(97.70%↑ Y/Y)
Accounts receivable, net
$347.3M
(249.75%↑ Y/Y)
Accrued expenses
-$116.9M
(-154.91%↓ Y/Y)
Issuances of common stock
under benefit plans
$127.7M
(11.43%↑ Y/Y)
Other financing
activities
$3.7M
(-40.32%↓ Y/Y)
Sales and maturities
of...
$5,897.4M
(32.06%↑ Y/Y)
Proceeds related to
equity securities
$16M
Net cash used in
financing activities
-$2,261.3M
(-51.27%↓ Y/Y)
Net cash used in
investing activities
-$945.4M
(74.92%↑ Y/Y)
Canceled cashflow
$131.4M
Canceled cashflow
$5,913.4M
Repurchases of common stock
$2,017.4M
(71.39%↑ Y/Y)
Payments in connection
with common stock...
$369.9M
(-8.67%↓ Y/Y)
Purchases of
available-for-sale debt securities
$6,396.5M
(-14.00%↓ Y/Y)
Payments on finance
leases
$5.4M
(-83.93%↓ Y/Y)
Purchases of property and
equipment
$437.6M
(46.99%↑ Y/Y)
Other investing
activities
$24.7M
(-54.26%↓ Y/Y)
Buy us a coffee